Wang Chih-Hwa, Wang Hui-Ting, Wu Kuan-Han, Cheng Fu-Jen, Cheng Cheng-I, Kung Chia-Te, Chen Fu-Cheng
Department of Emergency Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Emerg Med Int. 2022 Dec 30;2022:5389072. doi: 10.1155/2022/5389072. eCollection 2022.
Several risk scores have been developed to predict and analyze in-hospital mortality and short- and long-term outcomes of ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI); these can classify patients as having a high or low risk of death or complications.
To compare the prognostic precision of four risk scores for predicting in-hospital mortality in patients with STEMI treated with PPCI.
We performed a retrospective cohort analysis of patients with STEMI who underwent PPCI between 2012 and 2019 ( = 1346). GRACE (Global Registry of Acute Cardiac Events), CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications), Zwolle, and TIMI (Thrombolysis in Myocardial Infarction) risk scores were calculated for each patient according to different variables. We evaluated the predictive accuracy of these scores for in-hospital mortality using the statistic, which was obtained using logistic regression and receiver operating characteristic curves.
The GRACE, CADILLAC, Zwolle, and TIMI risk scores all had good predictive precision for in-hospital mortality, with C statistics ranging from 0.842 to 0.923. The GRACE and CADILLAC risk scores were found to be superior.
All GRACE, CADILLAC, Zwolle, and TIMI risk scores showed a high predictive value for in-hospital mortality due to all causes in patients with STEMI treated with PPCI. The GRACE and CADILLAC risk scores revealed a better accuracy for predicting in-hospital mortality than the Zwolle and TIMI risk scores.
已经开发了几种风险评分来预测和分析接受直接经皮冠状动脉介入治疗(PPCI)的ST段抬高型心肌梗死(STEMI)患者的院内死亡率以及短期和长期预后;这些评分可以将患者分类为死亡或并发症风险高或低。
比较四种风险评分对接受PPCI治疗的STEMI患者院内死亡率的预测准确性。
我们对2012年至2019年间接受PPCI的STEMI患者进行了一项回顾性队列分析(n = 1346)。根据不同变量为每位患者计算GRACE(全球急性心脏事件注册)、CADILLAC(阿昔单抗与降低晚期血管成形术并发症器械对照研究)、兹沃勒和TIMI(心肌梗死溶栓)风险评分。我们使用通过逻辑回归和受试者工作特征曲线获得的C统计量评估这些评分对院内死亡率的预测准确性。
GRACE、CADILLAC、兹沃勒和TIMI风险评分对院内死亡率均具有良好的预测准确性,C统计量范围为0.842至0.923。发现GRACE和CADILLAC风险评分更优。
对于接受PPCI治疗的STEMI患者,所有GRACE、CADILLAC、兹沃勒和TIMI风险评分对各种原因导致的院内死亡率均显示出较高的预测价值。与兹沃勒和TIMI风险评分相比,GRACE和CADILLAC风险评分在预测院内死亡率方面显示出更高的准确性。